Pathogenic effects of anti-citrullinated protein antibodies in rheumatoid arthritis – role for glycosylation - 28/02/19
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
The identification in 1998 of the main antigenic substrate recognized by autoantibodies was a dramatic turning point in our understanding of rheumatoid arthritis (RA) biology. Now, two decades later, antibodies to citrullinated proteins are viewed no longer as mere biomarkers for RA, but also as major pathophysiological factors involved in the development of bone loss and joint pain. These pathogenic effects are ascribable to abnormal autoantibody glycosylation via a pathway involving the Th17T cells. In the future, abnormal autoantibody glycosylation may serve as a disease activity biomarker and suggest novel treatment strategies.
Le texte complet de cet article est disponible en PDF.Keywords : Rheumatoid arthritis, Anti-citrullinated protein antibodies, Anti-cyclic citrullinated peptide antibodies, ACPAs, Anti-CCPs. Sialylation
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?